Navigation Links
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
Date:4/25/2013

LAVAL, Quebec, April 25, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ("VPI") to purchase all of the outstanding shares of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") for a price of $24 per share in cash, without interest (less any applicable withholding taxes). 

The Offer expired at midnight, New York City time, on April 25, 2013.  American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has advised that, as of the expiration of the Offer, a total of 14,708,133 shares had been tendered into and not withdrawn from the Offer, representing approximately 84.12% of Obagi's outstanding shares.  Additionally, the depositary has advised that an additional 938,189 shares had been tendered by notice of guaranteed delivery. The condition to the Offer that at least a majority of the outstanding shares of Obagi common stock (on a fully diluted basis) be validly tendered and not properly withdrawn prior to the expiration of the Offer has been satisfied.  Accordingly, all shares that were validly tendered and not properly withdrawn were accepted for payment and Valeant will promptly pay for all such tendered shares in accordance with the terms of the Offer.  Valeant intends to exercise its top-up option to acquire additional Obagi shares.  As a result of the tenders and the top-up option exercise, Valeant will own more than 90% of the outstanding Obagi shares than 90% of the outstanding Obagi shares (on a fully diluted basis) and expects to complete today the acquisition of Obagi through a "short form" merger under Delaware law.

As a result of the merger, Obagi will become a wholly owned subsidiary of VPI.  In the merger, each remaining share of Obagi that was not validly tendered in the Offer will be cancelled and converted into the right to receive the same $24 per share in cash that was paid in the Offer.  Following completion of the merger, the common stock of Obagi will no longer be listed for trading on the NASDAQ Global Select Market, which is expected to take effect as of the close of market today.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Statements

This press release contains forward-looking statements regarding the  acquisition by Valeant of Obagi.  Statements including words such as "expects," "intends,"  "will,"  or similar expressions are forward-looking statements.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements are not guarantees of future events and involve risks and uncertainties.  All forward-looking statements speak only as of the date they were made.  The company assumes no obligation to publicly update any forward-looking statements, to reflect events, circumstances or changes in expectations after the date of this press release.

Contact Information:                                  

Laurie W. Little                                                                     
949-461-6002                                                                                                       laurie.little@valeant.com  

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. American Skin Association Announces New Member Of The Board J. Michael Pearson And New Education Council Member Ryan Weldon Of Valeant Pharmaceuticals International, Inc.
2. Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
3. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
4. Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
5. Valeant Pharmaceuticals Provides Update to Recent Event
6. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
7. Valeant Pharmaceuticals Announces Private Exchange Offer
8. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
9. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
10. Valeant Completes Acquisition Of Natur Produkt In Russia
11. Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - ... the North America continued to lead global ... translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... anti-bacterial market is inclined towards North America ...
(Date:2/8/2016)... -- Respiratory Devices - Medical Devices Pipeline Assessment, ... report, " Respiratory Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. The report ... comparative analysis of the products at various stages ... in the pipeline product development. It also provides ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , Feb. 8, ... Pharmaceuticals, Inc. (Medimetriks) today announced that they have entered ... commercialization rights for OPA-15406 in the U.S. and ... manufacturing rights.  OPA-15406 is a topical, non-steroidal phosphodiesterase IV ... --> --> In ...
Breaking Medicine Technology:
(Date:2/9/2016)... Texas (PRWEB) , ... February 09, 2016 , ... ... reconstruction firm helping businesses recover after a disaster, announced today the acquisition of ... companies in Hawaii. , “Investing in like-minded companies who excel at ...
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore ... help enterprises move workloads to the cloud. Cirracore provides a secure VMware® ... without traversing the Internet. Transformation Solutions (TSL Partners) provides a full range ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul ... appointment after they noticed their furnace not producing any heat. Shortly after entering the ... cracked heat exchanger was leaking dangerous levels of carbon monoxide into the home, at ...
(Date:2/9/2016)... California (PRWEB) , ... February 09, 2016 , ... ... of their new nationwide service to expand access to affordable hearing aids ... million hard of hearing individuals in the United States. , “For the average ...
(Date:2/9/2016)... ... February 09, 2016 , ... United ... In Praise of Prevention,” an animated video designed to prevent the ... translations of the video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, ...
Breaking Medicine News(10 mins):